Header Artwork
Header Artwork


The unusual suspects: E&L programs on transdermal, topical and oral drug products

March 22, 2021

10:00 am EST

Dries Cardoen

As part of the BioPharma Asia webinars series, Dries Cardoen will share some interesting insights in the risks of Extractables and Leachables on low-risk dosage forms. The webinar will be accessible through the BioPharma website; register below.

Most research on Extractables and Leachables is done on dosage forms that come with a high risk, like inhalation products, injectables, ophthalmics products, ect. In this webinar, Dries Cardoen will take a closer look at the reasons why low-risk dosage forms do not receive the same amount of attention and why they should. These dosage forms, like oral solutions, transdermal products and dermal products, are categorized by the USP to have a high likelihood of interaction with its packaging materials. The effects of Extractables and Leachables of these formulations are thus to be considered to guarantee the safety of the patients.

First there will be a short overview of the existing regulations concerning Extractables and Leachables in such low-risk dosage forms. The theoretical part is followed by a few hands-on cases. Examples of dermal, transdermal and oral solution products are given. The examples feature the analytical challenges, risk mitigation and toxicological concerns.


  • E&L programs on lower-risk dosage forms
  • Case studies on transdermal and dermal products
  • Case studies on oral solutions


Dries Cardoen

Dries Cardoen

Inhalation, Transdermal and Topical Drug Products Expert

Dries Cardoen received his Ph.D. from the Faculty of Biology at the University of Leuven (Belgium) in 2011. After his academic career as a post-doctoral researcher, he started at Nelson Labs Europe in 2013 as Study Director in the Extractables & Leachables Department. He is currently responsible for the group of study directors that is...